drugset / Trial / NCT03060434

Pentoxifylline and Lumbar Radiculopathy

NCT03060434

Phase 4 Active not recruiting 67 enrolled St Joseph University, Beirut, Lebanon
RandomizedCrossoverDouble-blindTreatment

Summary

The objective of this prospective controlled crossover study is to evaluate the efficacy and safety of pentoxifylline per os (800 mg daily) in the management of lumbar radiculopathy

Timeline

Start
2018-06-01
Primary completion
2022-12-01
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pentoxifylline Small molecule 400 mg Oral
Background Acetaminophen Small molecule 1 g
Comparator Ibuprofen Small molecule 600 mg
Background Pregabalin Small molecule 75 mg